Trial reportRespiratory research2025
Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [
Trial report in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PET/CT Study of Biodistribution and Performance of the [68Ga]Ga-DOTA-Siglec-9 in Patients With Rheumatoid Arthritis,Vasculitis or Pulmonary Sarcoidosis, and Radiation Dosimetry, Pharmacokinetics, Biodistribution, Safety and Tolerability in Healthy Men
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundSarcoidosis is a multisystem granulomatous disease of unknown etiology, with pulmonary involvement being the most common and clinically significant manifestation. Vascular adhesion protein-1 (VAP-1) plays a key role in leukocyte trafficking to inflamed tissues. [⁶⁸Ga]Ga-DOTA-Siglec-9 is a novel PET radiotracer that binds to VAP-1. This proof-of-concept study aimed to evaluate the feasibility of [68Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis.
methodsSix patients with stage 2 pulmonary sarcoidosis (age 50.5 ± 13.1 years; bodyweight 84.2 ± 14.7 kg), diagnosed by clinical, radiological, and histological findings, underwent [68Ga]Ga-DOTA-Siglec-9 PET/CT. Control subjects included six healthy male volunteers (age 37.5 ± 10.3 years; bodyweight 80.3 ± 3.9 kg) and one female patient with lung cancer (age 77 years; bodyweight 62 kg). Tracer uptake was quantified in the lungs, mediastinal lymph nodes, and organs involved in systemic inflammation.
resultsPatients with sarcoidosis showed significantly higher [68Ga]Ga-DOTA-Siglec-9 uptake in the lungs (SUVmean 1.82 ± 0.52 vs. 0.41 ± 0.08; P = 0.00006) and mediastinal lymph nodes (SUVmean 2.06 ± 0.46 vs. 0.89 ± 0.26; P = 0.0003) compared to healthy controls. Increased uptake was also observed in the liver (SUVmean 1.18 ± 0.14 vs. 0.80 ± 0.10, P = 0.0003), spleen (SUVmean 1.13 ± 0.09 vs. 0.82 ± 0.06, P = 0.00003), bone marrow (SUVmean 0.30 ± 0.12 vs. 0.06 ± 0.05, P = 0.001), and bone (SUVmean 0.27 ± 0.11 vs. 0.08 ± 0.04, P = 0.004), indicating systemic inflammation.
conclusionsThis proof-of-concept study demonstrates the potential of VAP-1-targeted [68Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis and associated inflammatory activity. Further validation in larger cohorts is warranted.
trial registrationClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.